scholarly journals Review of hepatobiliary contrast agents: Current applications and challenges

2018 ◽  
Vol 11 (1) ◽  
pp. 22-26
Author(s):  
Alex Frydrychowicz
Keyword(s):  
Contrast Agents ◽  
Hepatobiliary Contrast Agents

159. A CT EVALUATION OF THREE HEPATOBILIARY CONTRAST AGENTS

1984 ◽  
Vol 19 (5) ◽  
pp. S40
Author(s):  
R. Stude ◽  
L. Hedlund ◽  
G. A. Johnson ◽  
W. M. Thompson
Keyword(s):  
Contrast Agents ◽  
Ct Evaluation ◽  
Hepatobiliary Contrast Agents

Contrast-enhanced MR angiography in rats with hepatobiliary contrast agents

2004 ◽  
Vol 22 (7) ◽  
pp. 937-942 ◽  
Author(s):  
Kohki Yoshikawa ◽  
Yusuke Inoue ◽  
Morio Shimada ◽  
Masaaki Akahane ◽  
Sayaka Itoh ◽  
...  
Keyword(s):  
Contrast Agents ◽  
Mr Angiography ◽  
Contrast Enhanced ◽  
Hepatobiliary Contrast Agents

scholarly journals The role of gadoxetic acid as a paramagnetic contrast medium in the characterization and detection of focal liver lesions: a review

2015 ◽  
Vol 48 (1) ◽  
pp. 43-51 ◽  
Author(s):  
Renata Lilian Bormann ◽  
Eduardo Lima da Rocha ◽  
Marcelo Longo Kierzenbaum ◽  
Bruno Cheregati Pedrassa ◽  
Lucas Rios Torres ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Contrast Agent ◽  
Contrast Agents ◽  
Magnetic Resonance Images ◽  
Gadoxetic Acid ◽  
Focal Liver Lesions ◽  
Liver Lesions ◽  
Agent Based ◽  
Contrast Enhanced ◽  
Hepatobiliary Contrast Agents

Recent studies have demonstrated that the use of paramagnetic hepatobiliary contrast agents in the acquisition of magnetic resonance images remarkably improves the detection and differentiation of focal liver lesions, as compared with extracellular contrast agents. Paramagnetic hepatobiliary contrast agents initially show the perfusion of the lesions, as do extracellular agents, but delayed contrast-enhanced images can demonstrate contrast uptake by functional hepatocytes, providing further information for a better characterization of the lesions. Additionally, this intrinsic characteristic increases the accuracy in the detection of hepatocellular carcinomas and metastases, particularly the small-sized ones. Recently, a hepatobiliary contrast agent called gadolinium ethoxybenzyl dimeglumine, that is simply known as gadoxetic acid, was approved by the National Health Surveillance Agency for use in humans. The authors present a literature review and a practical approach of magnetic resonance imaging utilizing gadoxetic acid as contrast agent, based on patients' images acquired during their initial experiment.

Ferrioxamine B derivatives as hepatobiliary contrast agents for magnetic resonance imaging

1991 ◽  
Vol 22 (1) ◽  
pp. 88-100 ◽  
Author(s):  
Kurt A. Muetterties ◽  
Betty-Ann Hoener ◽  
Barry L. Engelstad ◽  
Jose M. Tongol ◽  
Mats G. Wikstrom ◽  
...  
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Resonance Imaging ◽  
Ferrioxamine B ◽  
Hepatobiliary Contrast Agents

scholarly journals Comparison of LI-RADS v.2017 and ESGAR Guidelines Imaging Criteria in HCC Diagnosis Using MRI with Hepatobiliary Contrast Agents

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Grzegorz Rosiak ◽  
Joanna Podgorska ◽  
Edyta Rosiak ◽  
Andrzej Cieszanowski
Keyword(s):  
Contrast Agents ◽  
Area Under Curve ◽  
Consensus Statement ◽  
Statistical Significance ◽  
Clinical Use ◽  
Diagnostic Ability ◽  
Extra Effort ◽  
Hepatobiliary Contrast Agents ◽  
Sensitivity Specificity ◽  
Better Than

Purpose. The purpose of this study was to assess and compare diagnostic ability of LI-RADS (LR) v. 2017 and ESGAR guidelines in hepatocellular carcinoma (HCC) diagnosis using MRI with hepatobiliary contrast agents.Methods. Seventy pathologically confirmed lesions in 32 patients (24 males and 8 females) who had MRI with hepatobiliary contrast done before surgery or biopsy were reviewed retrospectively. Six lesions were <10mm, 31 lesions 10-19mm, and 33 lesions ≥20mm. Two readers assessed all lesions according to LI-RADS v.2017 criteria and ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Statistical analysis was performed to compare diagnostic ability of both guidelines including receiver operative curves (ROC) and area under curve (AUC).Results. For LR ≥ 4 sensitivity, specificity, accuracy, and AUC were 96%, 75%, 88.6%, and 85.5, respectively. For LR5 they were 74%, 95%, 80%, and 84.5, respectively. For ESGAR criteria with major and additional features, they were 88%, 75%, 84.3%, and 81.5, respectively. For ESGAR criteria only with major features they were 78%, 80%, 78.6%, and 79, respectively. AUC analysis revealed that overall diagnostic ability of LI-RADS was higher than ESGAR but the results did not show statistical significance.Conclusions. Both LI-RADS and ESGAR guidelines presented high diagnostic ability in HCC diagnosis of MRI studies with hepatobiliary contrast agents. More complex LI-RADS criteria performed better than ESGAR guidelines and it may justify extra effort that needs to be put in the report. However, the results were not statistically different and the simplicity of the ESGAR guidelines should also be taken into consideration.

Sign in / Sign up

Export Citation Format

Share Document